Table 4. Medical providers’ use of patient delivered partner therapy within subgroups of patients during baseline and intervention periods.
Population Characteristic | Baseline | Intervention | ||||||
---|---|---|---|---|---|---|---|---|
Total | N | Weighted Percenta | 95% CIb | Total | N | Weighted Percenta | 95% CIb | |
Totalc | 580 | 110 | 18.3% | 15.3–21.7 | 4,701 | 1,598 | 34.0% | 32.6–35.4 |
Age | ||||||||
14–19 y | 199 | 41 | 20.5% | 15.5–26.7 | 1,509 | 510 | 33.9% | 31.5–36.3 |
20–24 y | 205 | 41 | 19.1% | 14.2–25.2 | 1,851 | 652 | 35.2% | 33.0–37.4 |
25–29 y | 95 | 13 | 13.0% | 7.5–21.6 | 775 | 265 | 34.2% | 31.0–37.6 |
30–34 y | 50 | 10 | 19.2% | 10.3–33.0 | 299 | 104 | 34.8% | 32.2–37.5 |
35–44 y | 22 | 3 | 12.9% | 3.7–36.4 | 185 | 55 | 29.5% | 23.2–36.6 |
>45 y | 6 | 0 | 0% | — | 67 | 9 | 13.3% | 6.9–24.0 |
Race | ||||||||
White | 331 | 74 | 22.2% | 18.0–27.0 | 2,465 | 913 | 37.3% | 35.4–39.2 |
Black | 55 | 6 | 10.0% | 4.3–21.5 | 446 | 101 | 22.7% | 19.0–26.8 |
Native American | 14 | 4 | 29.0% | 9.8–60.5 | 96 | 36 | 37.4% | 28.2–47.6 |
Asian | 18 | 2 | 10.8% | 2.2–38.9 | 143 | 65 | 45.5% | 37.4–53.8 |
Other | 22 | 2 | 8.7% | 1.9–32.3 | 255 | 120 | 47.0% | 41.0–53.1 |
Multiple | 16 | 3 | 17.7% | 4.8–47.8 | 102 | 40 | 39.5% | 30.4–49.4 |
Unknown | 124 | 19 | 15.1% | 9.7–22.7 | 1,194 | 323 | 27.0% | 24.6–29.6 |
Ethnicity | ||||||||
Hispanic | 140 | 31 | 21.5% | 15.4–29.2 | 958 | 418 | 43.9% | 40.7–47.1 |
Non-Hispanic | 366 | 70 | 18.3% | 14.7–22.5 | 3,343 | 1,074 | 32.0% | 30.4–33.6 |
Unknown | 74 | 9 | 12.4% | 6.5–22.3 | 400 | 106 | 26.7% | 22.6–31.2 |
Gender | ||||||||
Female | 456 | 104 | 22.6% | 19.0–26.6 | 3,704 | 1,437 | 39.2% | 37.6–40.8 |
Male | 124 | 6 | 4.7% | 2.1–10.3 | 997 | 161 | 16.6% | 14.4–19.0 |
Diagnosis | ||||||||
Chlamydia only | 515 | 106 | 19.8% | 16.6–23.4 | 4,333 | 1,523 | 35.2% | 33.8–36.6 |
Gonorrhea only | 55 | 2 | 3.6% | 0.7–16.2 | 253 | 56 | 22.1% | 18.4–26.4 |
Both | 21 | 2 | 8.8% | 1.8–33.3 | 115 | 19 | 16.0% | 10.4–23.9 |
Provider type | ||||||||
Family planning | 170 | 49 | 28.7% | 22.3–36.1 | 1,198 | 640 | 53.5% | 50.7–56.3 |
Women’s health | 51 | 12 | 23.9% | 13.9–37.9 | 454 | 212 | 47.4% | 42.8–52.0 |
Private | 113 | 16 | 13.7% | 8.5–21.4 | 1,216 | 381 | 31.3% | 28.8–34.0 |
ER/urgent care | 49 | 3 | 5.4% | 1.6–16.9 | 507 | 54 | 10.6% | 8.2–13.6 |
Military | 16 | 2 | 10.7% | 2.0–41.8 | 329 | 47 | 14.3% | 10.9–18.5 |
Other | 120 | 16 | 12.2% | 7.3–19.7 | 836 | 208 | 24.9% | 22.0–28.0 |
Unknown | 61 | 12 | 19.3% | 11.1–31.5 | 161 | 56 | 35.3% | 28.2–43.1 |
IPP clinicsd | ||||||||
IPP clinic | 214 | 59 | 26.9% | 21.4–33.2 | 1,457 | 728 | 49.9% | 47.4–52.5 |
Not IPP clinic | 366 | 51 | 13.4% | 10.3–17.2 | 3,244 | 870 | 26.8% | 25.3–28.4 |
aEstimated based on interviews with randomly sampled, interviewed patients.
bConfidence interval accounts for weighting; computed on logit scale and backtransformed.
cThe magnitude of the intervention effect did not vary significantly for any of the subgroups defined in the table.
dClinics that provided C. trachomatis outcome data.
ER, emergency room.